

## Human Engineered Heart Tissue: Analysis of Contractile Force

Ingra Mannhardt,<sup>1</sup> Kaja Breckwoldt,<sup>1</sup> David Letuffe-Brenière,<sup>1</sup> Sebastian Schaaf,<sup>1</sup> Herbert Schulz,<sup>2,3</sup> Christiane Neuber,<sup>1</sup> Anika Benzin,<sup>1</sup> Tessa Werner,<sup>1</sup> Alexandra Eder,<sup>1</sup> Thomas Schulze,<sup>1</sup> Birgit Klampe,<sup>1</sup> Torsten Christ,<sup>1</sup> Marc N. Hirt,<sup>1</sup> Norbert Huebner,<sup>2</sup> Alessandra Moretti,<sup>4</sup> Thomas Eschenhagen,<sup>1,5</sup> and Arne Hansen<sup>1,5,\*</sup>

<sup>1</sup>Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany

<sup>2</sup>Max-Delbrueck-Center for Molecular Medicine – MDC, DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 13092 Berlin, Germany

<sup>3</sup>Cologne Center for Genomics (CCG), University of Cologne, 50931 Cologne, Germany

<sup>4</sup>I. Medical Department - Cardiology, Klinikum rechts der Isar – Technische Universität München, DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, 81675 Munich, Germany

<sup>5</sup>Co-senior author

\*Correspondence: [ar.hansen@uke.de](mailto:ar.hansen@uke.de)

<http://dx.doi.org/10.1016/j.stemcr.2016.04.011>

### SUMMARY

Analyzing contractile force, the most important and best understood function of cardiomyocytes *in vivo* is not established in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). This study describes the generation of 3D, strip-format, force-generating engineered heart tissues (EHT) from hiPSC-CM and their physiological and pharmacological properties. CM were differentiated from hiPSC by a growth factor-based three-stage protocol. EHTs were generated and analyzed histologically and functionally. HiPSC-CM in EHTs showed well-developed sarcomeric organization and alignment, and frequent mitochondria. Systematic contractility analysis (26 concentration-response curves) reveals that EHTs replicated canonical response to physiological and pharmacological regulators of inotropy, membrane- and calcium-clock mediators of pacemaking, modulators of ion-channel currents, and proarrhythmic compounds with unprecedented precision. The analysis demonstrates a high degree of similarity between hiPSC-CM in EHT format and native human heart tissue, indicating that human EHTs are useful for preclinical drug testing and disease modeling.


### INTRODUCTION

The advent of human induced pluripotent stem cell (hiPSC) technology and protocols to efficiently differentiate cardiomyocytes (CM) (Burridge et al., 2012) have opened the perspective to use hiPSC-CM for cardiac research or drug development. This biotechnology advancement also boosted the development of test systems to evaluate hiPSC-CM electrophysiology (reviewed in Hoekstra et al., 2012), impedance (Guo et al., 2013; Scott et al., 2014), field potentials (Caspi et al., 2009; Harris et al., 2013; Navarrete et al., 2013; Clements and Thomas, 2014; Riedel et al., 2014; Qu and Vargas, 2015), action potentials and calcium transients with fluorescent dyes, and cellular shortening video-optically (Lee et al., 2012; Lopez-Izquierdo et al., 2014; Feaster et al., 2015; Pointon et al., 2015). These assays may improve preclinical drug development and safety toxicology, because current systems are based either on recombinant cell lines or animal cells, both susceptible to typical shortcomings. HiPSC-CM promise an intact, human cardiomyocyte context in which a drug and/or principle is tested. Moreover, patient-specific cell lines offer (1) the perspective of testing drugs in a wide spectrum of genetic backgrounds and (2) individualized risk prediction and testing of adverse drug effects. Different technologies have been employed for predictive toxicology application (Braam et al., 2010; Pointon

et al., 2015), and many studies have successfully demonstrated disease-specific phenotypes in hiPSC-CM from patients with inherited cardiac diseases (reviewed in Moretti et al., 2013; Karakikes et al., 2015). Most test systems use hiPSC-CM as 2D layers on rigid plastic cell-culture dishes that do not allow the cells to perform physiological auxotonic contractions (Nishimura et al., 2004). Contractile function, the main feature of the heart, can only be analyzed in a very restricted manner.

We have developed protocols to form 3D force-generating engineered heart tissues (EHTs; Eschenhagen et al., 2012; Hirt et al., 2014). This follows the principle of hydrogel formation with dissociated cardiomyocytes in casting molds and maintenance with a defined preload. Cardiomyocytes remodel the hydrogel, align along force lines, increase in size, and form a coherently beating syncytium. Potential advantages of the EHT system for preclinical drug development and safety toxicology are 2-fold. (1) It allows monitoring effects of drugs on all major parameters of heart function: force, pacemaking activity and contraction, and relaxation kinetics. (2) The analysis is done under stable conditions that resemble cardiac physiology, i.e., 3D heart-like muscle strips that contract under auxotonic, work-performing, steady-state conditions.

First publications with EHTs from human embryonic stem cells or hiPSC-CM demonstrated the principal



**Figure 1. Cardiac Differentiation Protocol**


Spontaneous beating started at days 9–11 of differentiation. Beating cells were dissociated, subjected to fluorescence-activated cell sorting analysis (cTNT), and used for EHT generation (d14; see also [Movies S4](#) and [S5](#)). EHTs started coherent beating at days 10–14 after casting and enabled for functional analysis (see also [Movie S1](#); scale bar, 1 mm). Average contraction peaks of spontaneously beating (black) and electrically paced EHTs (red; 1.5 Hz; 20–35 days after casting) in modified Tyrode's solution with 1.8 mM calcium are shown ( $n = 50$  EHTs from seven independent experiments per group; depicted are mean  $\pm$  SEM). Scale bars, 200  $\mu$ m. See also [Figure S1](#).

feasibility to generate human constructs and some basic characterization ([Schaaf et al., 2011](#); [Tulloch et al., 2011](#); [Kensah et al., 2013](#); [Nunes et al., 2013](#); [Thavandiran et al., 2013](#)). However, neither we nor others have yet shown that EHTs from hiPSC-CM are indeed suitable for the proposed purpose, i.e., whether they faithfully replicate effects on indicator compounds affecting rate, force, and contraction kinetics. This is particularly important for inotropes, since modulators of inotropy are a mainstay of cardiac drug development and new concepts are urgently needed ([Francis et al., 2014](#)). The present study therefore set out to answer the following questions. (1) Do drugs known to interfere with pacemaking mechanisms in the sinoatrial node (SAN) affect the spontaneous beating rate of hiPSC-EHTs? (2) Do positive and negative inotropic drugs affect contraction force of hiPSC-EHTs in a manner similar to that of human heart muscle strips? (3) Do drugs with known and supposedly specific effects on individual ion currents affect contractile function? (4) Is prolongation of relaxation time a surrogate for prolongation of repolarization and proarrhythmic risk?

## RESULTS

### Differentiation Results and Baseline Characterization of hiPSC-EHTs

Formation of embryoid bodies (EBs) in spinner flasks resulted in homogeneous EBs of  $54 \pm 1 \mu\text{m}$  ( $n = 198$ ) diameter. The average differentiation efficiency was  $87\% \pm 9\%$  ( $n = 20$ ) with an input/output ratio of  $1:1.2 \pm 0.8$  (hiPSC/hiPSC-CM). Human EHTs started to beat spontaneously and regularly 10–14 days after casting and continued for several weeks (25- and 74-day-old EHT are shown in [Movies S1](#) and [S2](#)). Baseline contractility parameters under auxotonic conditions (20- to 25-day-old EHTs from seven different cardiomyocyte batches;  $n = 75/7$ ) were  $61 \pm 2$  bpm (frequency),  $0.152 \pm 0.006$  mN (force),  $0.120 \pm 0.002$  s (T1, contraction time),  $0.163 \pm 0.003$  s (T2, relaxation time),  $1.51 \pm 0.07$  mN/s (maximal contraction velocity), and  $1.11 \pm 0.06$  mN/s (maximal relaxation velocity). Average peaks of spontaneously beating and electrically paced EHTs ( $n = 50$ ) are shown in [Figure 1](#). During cardiac differentiation, expression of the pluripotency



**Figure 2. Histological Evaluation of hiPSC-EHTs**


(A) Representative still view of a living EHT. (B) Longitudinal section stained with H&E. (C) Cross section stained for dystrophin. (D) Longitudinal section stained for MLC2v. (E) Whole-mount immunofluorescence confocal microscopic section of EHT stained with DRAQ5 (nuclei, blue) and  $\alpha$ -actinin (green). (F) Confocal analysis of hiPSC-CM cultured in 2D for 30 days stained with DRAQ5 (blue) and antibodies against cardiac MLC2v (red) and  $\alpha$ -actinin (green). (G and H) Whole-mount immunofluorescence confocal microscopic section of 30- to 35-day-old EHTs stained with DRAQ5 (blue) and antibodies against  $\alpha$ -actinin (red; G) and caveolin-3 (green; G) or phalloidin (red; H) and an antibody against junctophilin-2 (green; H). (I) Transmission electron microscopy of 35-day-old EHT. Arrows indicate structures resembling t tubules. See also [Figure S2](#).

gene *OCT-4* declined, expression of mesoderm genes (*MESP*, *VEGFR2*) increased transiently, and expression of cardiac genes increased progressively ([Figure S1A](#)). Differentiated cardiomyocytes were mainly MLC2a<sup>+</sup>/MLC2v<sup>-</sup> and developed to an MLC2a<sup>-</sup>/MLC2v<sup>+</sup> cardiomyocyte population in the EHT format ([Figures S1B](#) and [S1C](#)). The non-cardiomyocyte fraction at the end of differentiation was investigated by gene-expression analysis. Besides cardiac genes, the most prominently expressed genes were those typical for (myo)fibroblast-like cells, while genes for other cell types were expressed below 1% of cardiac gene expression level ([Figure S1D](#)).

Still pictures of live EHTs taken with the video camera of the EHT setup ([Figure 2A](#) and [Movie S1](#)) demonstrated macroscopically distinguishable muscle bundles in EHTs. Histological analysis of 30- to 35-day-old EHTs revealed structural anisotropy with cellular alignment in parallel to the force lines spanning along the longitudinal axis of the tissue ([Figure 2B](#)) and appearing as round, dystrophin-positive CM in cross sections ([Figure 2C](#)). CM in EHTs were characterized by regular sarcomeric organization of  $\alpha$ -actinin and a high degree of MLC2v-positive CM ([Figures 2D](#) and [2E](#)), whereas CM cultured in 2D showed poor sarcomeric organization and less cellular

alignment ([Figure 2F](#)). Caveolin-3 immunofluorescence provided initial evidence for immature t-tubule formation by demonstrating punctual but irregular staining pattern and areas with poorly organized caveolin-3-positive structures as an indicator for developing caveolae ([Figure 2G](#)). This irregular staining pattern was also apparent in EHTs stained with an antibody against junctophilin-2 ([Figure 2H](#)). Transmission electron microscopy (TEM) confirmed orientation and alignment of sarcomeric structures with regular Z lines, and inconsistent I- and A-band formation ([Figure 2I](#)). Average sarcomere length was  $1.6 \pm 0.1 \mu\text{m}$  ( $n = 20$  sarcomeres); mitochondria were frequent and exhibited mainly immature cristae-subtype with sparse cristae formation. Tubular structures ( $\sim 60\text{--}80$  nm diameter) were detected in close proximity to Z lines. Gene expression of ion channels and cardiac markers indicated overall similar expression in EHT and 2D ([Figures S2A](#) and [S2B](#)). Microarray analysis ([Table S1](#); NCBI GEO accession number GEO: GSE80390) of differentiated cardiomyocytes, EHT, and 2D CM samples revealed 5,687 significantly expressed genes (false-discovery rate [FDR] <5%, [Table S1](#)). Probes below 0.1% FDR ( $n = 277$ ) were further investigated using clustering ([Figure S2C](#)) and functional enrichment approaches ([Table S2](#)). Several





**Figure 3. Modulation of Spontaneous Beating Frequency of hiPSC-EHTs in Modified Tyrode's Solution**

Replicates are indicated as EHTs/number of independent experiments. Data are depicted as mean  $\pm$  SEM (A and B) or scatter plots with means (C and D).

(A) Ivabradine effect at 1.8 mM calcium; n = 4/1.

(B) Effect of 100 nM isoprenaline (Iso), 10  $\mu$ M ryanodine (Ryd), or isoprenaline after ryanodine preincubation (Ryd + Iso, 5 min) at 0.6 mM calcium; n = 4–8/1.

(C) Effect of SEA-0400 at 1 mM calcium (1 hr incubation time); n = 12–16/2.

(D) Effect of tetrodotoxin (TTX) at 1.8 mM calcium; n = 16/2.

See also [Figure S3](#).

calcium-handling proteins (L-type calcium channels, LTCC;  $\text{Na}^+/\text{Ca}^{2+}$ -exchanger, NCX1;  $\text{Na}^+/\text{K}^+$ -ATPase;  $\text{Na}^+/\text{H}^+$ -exchanger, NHE1; SR  $\text{Ca}^{2+}$ -ATPase, SERCA; phospholamban [PLN]) were detected in 2D and EHT by western blot ([Figure S2E](#)).

### Functional Characterization of hiPSC-EHTs

The basis for the characterization of the hiPSC-EHT model are 26 concentration-response curves (CRC), depicted as scatterplots in [Figures S5–S7](#).


#### Pacemaker Mechanisms

To investigate pacemaker mechanisms in hiPSC-EHTs, we analyzed the contraction pattern by video-optical recording ([Figure S3](#)). We tested five compounds interfering relatively selectively with the membrane clock (ivabradine with hyperpolarization-activated cyclic nucleotide-gated [HCN] channels), the SR-based calcium clock (ryanodine with ryanodine receptors, SEA-0400 with NCX), or both proposed pacemaker mechanisms (isoprenaline with PLN and HCN channels) or sodium-channel activity (TTX). Ivabradine (0.01–1  $\mu$ M) concentration- and time-dependently decreased spontaneous beating frequency with half-maximal effects at  $\sim$ 50 nM and almost complete inhibition at 1  $\mu$ M ([Figures 3A](#) and [S7N](#)). Ryanodine (10  $\mu$ M) decreased the spontaneous beating rate (from  $47 \pm 6$  to  $20 \pm 2$  bpm; n = 4) and antagonized the positive chronotropic effect of isoprenaline ([Figure 3B](#)), which itself amounted to +27% (from  $47 \pm 6$  to  $60 \pm 4$  bpm). The NCX inhibitor SEA-0400 induced complex responses. Some EHTs showed an increase in spontaneous beating frequency and others a reduction, and some ceased beating at high concentrations (10  $\mu$ M, [Figures 3C](#) and [S7O](#)). TTX concentration-dependently decreased the beating rate

with a threshold concentration of 300 nM ([Figures 3D](#), [6B](#), [S6B](#), and [S6D](#)).

#### Physiological Force Modulation

HiPSC-EHTs displayed a concentration-dependent positive inotropic response to increasing extracellular calcium concentrations with an half maximal effective concentration ( $\text{EC}_{50}$ ) of 0.6 mM calcium (n = 8; Hill slope 1.96; [Figures 4A](#) and [S5A](#)). Under pacing, EHTs followed electrical stimulation between 1 and 2 Hz and partially lost capture above 2 Hz ([Figure 4B](#)). At pacing rates below 1 Hz, frequency-control was incomplete due to higher spontaneous beating frequency for some EHTs. An increase in beating rate between 1.0 and 2.0 Hz resulted in reduction of contraction time and relaxation time (frequency-dependent acceleration of relaxation [FDAR]  $-18\%$ ), but no change of contractile force (no Treppe phenomenon; [Figure 4C](#)).  $\beta$ -Adrenergic stimulation with isoprenaline (100 nM at 0.6 mM  $\text{Ca}^{2+}$ , 2-Hz pacing frequency) led to an increase in contractile force ( $+41\% \pm 7\%$ ; n = 13), no change in contraction time T1 ( $-2\% \pm 2\%$ ; n = 13), and a decrease in relaxation time T2 ( $-20\% \pm 4\%$ ; n = 13; [Figure S5B](#)). The positive lusitropic effect of isoprenaline was antagonized by the muscarinic agonist carbachol (10  $\mu$ M, T2  $+31\% \pm 5\%$  compared with isoprenaline; n = 13; [Figure 4D](#)). Increasing the preload resulted in an increase in contractile force from  $43\% \pm 5\%$  to 100% (maximum force; n = 9). Maximum force was reached at 107% of slack length ([Figure 4E](#)). Post-rest potentiation (PRP) was analyzed in the presence of SEA-0400 (10  $\mu$ M). This reduced the spontaneous beating rate and potentially aggravated the potentiation: After 200 s of pacing (1.5 Hz) a 20-s-long pacing pause was introduced before pacing was reinitiated. Comparison of the last contraction peak before and the first



**Figure 4. Regulation of Contractile Function of hiPS-EHTs by Physiological Interventions**

All experiments were carried out in modified Tyrode's solution; replicates are indicated as EHTs/number of independent experiments; error bars are SEM.

(A) Calcium concentration-response curve at 2-Hz electrical stimulation ( $n = 8/2$ ).

(B) Beating rate at pacing frequencies between 0.6 and 3.0 Hz ( $n = 8/1$ ).


(C) Force/contraction time/relaxation time-frequency relationship at 1.0 mM external calcium ( $n = 8/1$ ).

(D) Response of electrically stimulated (2 Hz) EHTs to 100 nM isoprenaline (Iso) and 10  $\mu$ M carbachol (Cch) at 0.6 mM calcium ( $n = 13/2$ ).

(E) Frank-Starling mechanism. Increase in force in relation to increased preload at 1.8 mM calcium and 2 Hz ( $n = 5-9/1$ ).

(F) Post-rest potentiation of EHTs at 1 mM calcium in the presence of 10  $\mu$ M SEA-0400. Representative example (20 s rest, pacing with 1.5 Hz) and statistical evaluation ( $n = 8/1$ ).

See also [Figure S4](#).



**Figure 5. Regulation of Contractile Function of hiPSC-EHTs by Inotropic Drugs**

Average contraction peaks before (black) and after (red) the respective inotropic drug intervention.

(A–H) Positive inotropic drugs (A–F) were tested at submaximal (0.5–0.6 mM), and negative inotropic drugs (G and H) at high (1.8 mM; H) and submaximal (0.5 mM; G) calcium concentrations. Depicted is the electrically stimulated (1.5–2 Hz) mean relative force in percentage of baseline maximum  $\pm$  SEM in modified Tyrode's solution; replicates are indicated as EHTs/number of independent experiments. (A) calcium (5 mM;  $n = 8/2$ ). (B) ouabain (100 nM;  $n = 6/2$ ). (C) Bay K-8644 (300 nM;  $n = 4/1$ ). (D) EMD-57033 (10  $\mu$ M;  $n = 4/1$ ). (E) isoprenaline (100 nM;  $n = 4/1$ ). (F) rolipram (10  $\mu$ M) + isoprenaline (100 nM, red) versus isoprenaline (100 nM, black;  $n = 11/2$ ). (G) ryanodine (0.3  $\mu$ M, red; 10  $\mu$ M, blue;  $n = 6/2$ ). (H) verapamil (1  $\mu$ M;  $n = 18/2$ ).

See also [Figure S5](#).

after the pacing pause revealed a PRP of +17% ( $n = 11$ ; [Figure 4F](#)). The selective inhibitor of the slowly activating delayed rectifier current  $I_{Ks}$ , HMR-1556, was tested in the presence of  $\beta$ -adrenergic activation and  $I_{Kr}$  inhibition, a protocol that revealed maximal contribution of  $I_{Ks}$  to repolarization in human ventricular myocardium ([Jost et al., 2005](#)). HMR-1556 slightly reduced the isoprenaline-stimulated spontaneous beating rate, but failed to affect relaxation time or force, whereas E-4031 increased relaxation time by +82% in an isoprenaline-sensitive manner ( $n = 4/1$ ; [Figure S4](#)).


#### Pharmacological Force Regulation

We analyzed the effect of positive and negative cyclic AMP (cAMP)-dependent and -independent inotropic modulators (calcium, ouabain, Bay K-8644, EMD-57033, isoprenaline, rolipram, ryanodine, and verapamil) under rate control (1–2 Hz). Average contraction peaks are depicted in [Figure 5](#) (complete CRCs are shown in [Figure S5](#)). These peaks demonstrate canonical inotropic changes for all compounds tested, associated with characteristic changes in contraction kinetics.  $Ca^{2+}$ , ouabain, and verapamil modulated force without a change in contraction kinetics, while the increase in force development in the presence of the cAMP-dependent drugs isoprenaline and rolipram was accompanied by the typical hastening of relaxation (positive lusitropic effect). Conversely, the  $Ca^{2+}$  channel agonist

Bay K-8644 and the myofilament  $Ca^{2+}$  sensitizer EMD-57033 markedly prolonged relaxation (negative lusitropic effect). Ryanodine displayed typical biphasic responses, with negative inotropic effects at low (0.3  $\mu$ M) and positive inotropic effects at high (10  $\mu$ M) concentrations and a pronounced increase in contraction time (T1), as shown for myocardium tissue ([Sutko and Willerson, 1980](#)).

#### Modulators of the Cardiac Ion Channels

Antagonists and agonists of ion channels were analyzed in spontaneously beating EHTs ([Figures 6](#) and [S6](#)). Delayed inactivation of the fast sodium current  $I_{Na}$  by ATX-II or activation of the L-type calcium current  $I_{Ca,L}$  by Bay K-8644 prolonged relaxation time T2 as did E-4031, a selective inhibitor of the repolarizing, rapidly activating delayed rectifier current  $I_{Kr}$ . ATX-II had the most pronounced effect (556%  $\pm$  31% of baseline; see also [Movie S3](#)), Bay K-8644 mainly inhibited early relaxation, and E-4031 induced typical after-contractions. Conversely, NS-1643, an agonist of  $I_{Kr}$ , concentration-dependently reduced T2, which was accompanied by increased spontaneous beating frequency and an increase in contractile force. At high concentrations (0.1 mM) EHTs demonstrated an irregular beating pattern, indicated by high scatter for all contractility parameters ([Figures 6D](#) and [S6G](#)). TTX slowed the spontaneous beating rate as seen before ([Figure 3D](#)), but did not have a major effect on force or contraction kinetics ([Figure S6D](#)). The  $I_{Ca,L}$



**Figure 6. Effect of Specific Ion-Channel Modulators on Spontaneous Contractions of hiPSC-EHTs**

Data are depicted as single values and mean; replicates are indicated as EHTs/number of independent experiments.

(A) Regular spontaneous beating pattern under baseline condition (left) and 3 hr later (time control, right).

(B–D) Concentration-response curves (B) Left: ATX-II ( $I_{Na}$  gating inhibitor, agonist;  $n = 20/2$ ); right: TTX ( $I_{Na}$  antagonist;  $n = 16/2$ ). (C) Left: Bay K-8644 ( $I_{Ca,L}$  agonist;  $n = 8/2$ ); right: verapamil ( $I_{Ca,L}$  antagonist;  $n = 19/2$ ). (D) Left: NS-1643 ( $I_{Kr}$  agonist;  $n = 20/3$ ); right: E-4031 ( $I_{Kr}$  antagonist;  $n = 20/3$ ).

Depicted are representative original recordings and concentration-response curve for the most sensitive contraction parameter ( $T_2$ , relaxation time at 80% relaxation, BPM, beats per minute). Blue arrows indicate published  $EC_{50}/IC_{50}$  values (Oliveira et al., 2004; Kaufmann et al., 2013; Bechem and Schramm, 1987; Ferry et al., 1985; Casis et al., 2006; Zhou et al., 1998). Statistical analysis was conducted by one-way ANOVA with Dunnett's post test versus baseline conditions (BL) for experiments with  $\geq 3$  independent experiments;  $*p < 0.05$ .

See also Figure S6.


antagonist verapamil concentration-dependently decreased contractile force (as seen before under electrical pacing, Figure 5H) and had only slight effects on contraction kinetics (Figure S6F). The expression of the respective ion channels was verified as stated above (Figure S2). To examine the compatibility of this protocol with cardiomyocytes from commercial sources, we also generated EHTs with Cor.4U and iCell CM. Figure S6A shows spontaneous and electrically stimulated average contraction peaks of Cor.4U and iCell EHTs compared with the in-

house reference cell line differentiated with the protocol described herein. The EHTs from these commercial cell lines responded similarly to the aforementioned ion-channel modulators (Figure S6B).

#### Proarrhythmic Compounds

Drug-induced increase in action potential duration ( $APD_{90}$ ) is an important indicator for proarrhythmic cardiotoxicity (Redfern et al., 2003). The results with the ion-channel model compounds ATX-II, Bay K-8644, and E-4031 indicated that relaxation time  $T_2$  of hiPSC-EHTs





**Figure 7. Correlation Analysis**

Correlation between threshold value (THV) for prolongation of relaxation time (T<sub>2</sub>, EHT) and increase in APD<sub>90</sub> (10%–20%, Redfern et al., 2003), Pearson correlation  $R^2 = 0.80$ . See also Figure S7.

might be a suitable surrogate parameter for repolarizing time or APD<sub>90</sub>. We therefore determined the effect of ten known proarrhythmic compounds and, in line with the often complex, nonselective actions of these compounds, observed concentration-dependent effects on spontaneous beating frequency, force, and T<sub>2</sub> (Figures S7A–S7J). We plotted threshold values of T<sub>2</sub> prolongation against published concentrations of these compounds, increasing APD<sub>90</sub> by 10%–20% (Figure 7; Redfern et al., 2003). This analysis demonstrates a very strong correlation between these two parameters (correlation coefficient  $R^2 = 0.80$ ). On the other hand, cardio-safe drugs (verapamil, ampicillin, paracetamol, aspirin; Figures S6F and S7K–S7M) did not affect T<sub>2</sub> in this model.

## DISCUSSION

In this study we evaluated the morphology and function of engineered 3D heart muscle strips (EHTs) from hiPSC-CM and their suitability for drug screening. The protocol allows analysis of contractile force with high levels of automation but requires  $1 \times 10^6$  cells per EHT and 14 days of incubation time after casting. Our main findings are as follows. (1) The EHT format supports excellent heart muscle formation and morphological maturation of hiPSC-CM. (2) Modulation of beating frequency by isoprenaline, ivabradine, ryanodine, SEA-0400, and TTX suggests both calcium- and membrane-clock mechanisms to be involved in spontaneous pacemaking of hiPSC-CM/EHTs and an overall similarity with newborn SAN pacemaking. (3) Human iPSC-EHTs exhibited a positive force-length relationship and FDAR and PRP, but a neutral force-frequency relationship. (4) Canonical responses to cAMP-dependent and -independ-

ent positive and negative inotropic drugs were observed. (5) There was high sensitivity and specificity for selective ion-channel modulators; several proarrhythmic and safe drugs make hiPSC-EHT a promising model for preclinical drug screening.

Less than a decade after the establishment of the first protocol for the generation of hiPSC (Takahashi et al., 2007), CM can now be differentiated from hiPSC at high efficiency and are commercially available. Thus, hiPSC-CM are increasingly used for biomedical applications and have a chance to partially replace the mouse, with its known limitations, as the standard model in cardiovascular research. Yet the true value of hiPSC remains controversial, in part because of limited functional readout assays. Our study addressed these issues and tried to answer via a systematic approach to what extent the automated 24-well hiPSC-EHT assay is suitable as a robust, high-content contractile force assay.

The experimental design of this model provides several differences to standard 2D culture: EHTs are anchored between two flexible silicone posts, which generate a preload, and EHTs perform auxotonic contractile work (the physiological form of cardiac contraction) against elastic posts. This results in macroscopically distinguishable muscle bundles, a high degree of CM alignment and orientation, good sarcomeric organization, and cross-striated CM approaching the classical rod shape of adult ventricular myocytes. These results compare favorably with human embryonic stem cell- and hiPSC-CM cultured in classical monolayers that are polymorphic and small, isotropically oriented, and have disarrayed sarcomeres and very immature ultrastructural organization (reviewed in Yang et al., 2014). Furthermore, TEM, confocal immunofluorescence microscopy, and western blot analysis revealed that CM in EHTs have a relatively high mitochondrial density and express classical calcium-handling proteins. TEM and staining for caveolin and junctophilin are compatible with nascent t tubules, but the data clearly do not qualify as proof of an established t-tubular system in hiPSC-CM in EHTs. Others have shown that culture time is important for the structural and functional development of hiPSC-CM in 2D (Lundy et al., 2013) and that 1-year-old CM cultured at very low density exhibits increased size, longer and better organized sarcomeres, greater transcript levels of cardiac marker proteins, longer action potentials, and signs of metabolic switch that could be mimicked by overexpressing the microRNA let-7 (Kuppasamy et al., 2015). Since EHTs are cultured for only 2–3 weeks before the first measurements, other factors such as the 3D heart muscle-like environment and load likely participate in this development process. The impact of load on cardiomyocyte development is also supported by a recent study in neonatal rat EHTs demonstrating that increasing the load





by inserting metal braces induced a phenotype of pathological cardiac hypertrophy in rat EHTs (Hirt et al., 2012), indicating that culture under isometric conditions (stiff posts or 2D cultures on plastic surfaces) may in fact induce a pathological phenotype. Somewhat surprisingly, EHTs could readily be generated not only from hiPSC-CM preparations with 60%–90% purity, but also from two commercially available hiPSC-CM (CDI, Axiogenesis), which, by genetic selection, are essentially free of non-myocytes, suggesting that previous findings of a mandatory requirement of 25% non-cardiomyocytes in collagen-based EHTs (Naito et al., 2006) do not apply for human tissues generated with fibrin.

Contractile force in CM is the result of a fine-tuned interplay between electrical activation, calcium handling, and myofilament activation. To obtain a comprehensive picture of inotropic regulation in hiPSC-EHT, we analyzed the effects of eight compounds (calcium, ouabain, Bay K-8644, EMD-57033, isoprenaline, rolipram, ryanodine, and verapamil) that modulate contractile function by different modes of action. The data suggest that the hiPSC-EHT model replicates characteristic effects on inotropy and kinetics of contraction. The level of precision in replicating inotropic effects in hiPSC-EHTs is, to the best of our knowledge, unmatched by other approaches. For example, edge detection in 2D hiPSC-CM demonstrated high sensitivity and specificity in detecting modulators of inotropy, but failed to discriminate positive from negative inotropic agents (Pointon et al., 2015). The positive inotropic effects described in our study are smaller than in human non-failing heart tissue (Figure S5F). These differences are likely related to a lack of full maturation of CM in hiPSC-EHTs: Mitochondrial density and substructure, sarcomeric organization, intercellular connections, and t tubules are still clearly less developed in hiPSC-CM in EHTs than in native heart tissue. EHTs beat spontaneously, regulation of contractile function by physiological interventions was smaller, and a force-frequency relationship was absent. A key prerequisite for inotropic responses of CM is the precise spatial configuration of t tubules and sarcoplasmic reticulum. Even though PRP indicated functional sarcoplasmic reticulum and TEM analysis/caveolin-3/junctophilin-2 immunofluorescence suggests tubular structures in close proximity to Z lines, the irregularity and the small size indicate a very immature t-tubule/SR system. In native myocytes, the t-tubule microarchitecture is highly organized with distances to the SR of 12–15 nm. Small deviations of the spatial distance have been associated with altered calcium-induced calcium-release mechanism (Gómez et al., 1997). The much greater abnormalities of the t-tubule/SR organization in hiPSC-CM would also be compatible with the lack of a force-frequency relationship. Along the same lines, detubulation of rat myocytes by

formamide-induced osmotic shock was associated with prolonged contraction peaks and calcium transients, and lack of a positive force-frequency relationship, but a preserved FDAR, positive force-calcium relationship, and positive PRP (Ferrantini et al., 2014). A study comparing human ventricular heart tissue of newborns (<2 weeks) and infants (3–15 months) observed t tubules, positive force-frequency relationship, and FDAR in infants, but only FDAR in newborns (Wiegerinck et al., 2009). PRP is directly related to the capacity of the SR to store and release calcium. The small PRP in hiPSC-EHTs suggest that the SR is incompletely developed, but functional. The link between small PRP and immaturity is also supported by a previous study demonstrating an increase in PRP with rabbit cardiomyocyte maturation between postnatal days 1–4, 14–21, and >180 (Boucek et al., 1987). On the other hand, while non-failing human heart tissue has been mainly evaluated under isometric conditions, force in hiPSC-EHTs is measured under physiological auxotonic conditions. The impact of this difference is not well characterized, but one study demonstrated 50% lower forces for auxotonic versus isometric conditions in adult rat ventricular CM (Nishimura et al., 2004).

Pacemaking in SAN cells is a complex process, explained by a combination of ion fluxes across the sarcolemmal membrane and the SR, designated as the calcium and membrane clocks (Lakatta et al., 2010). The mechanisms of spontaneous beating in hiPSC-CM are not well understood. Previous studies identified  $I_f$  current in hiPSC-CM (Ma et al., 2011). The marked efficacy and potency ( $EC_{50} \sim 50$  nM) of the  $I_f$  inhibitor ivabradine to reduce the beating rate in our study provide evidence for a major role of this current and, therefore, the membrane clock, for pacemaking in hiPSC-EHTs. Both potency and efficacy of ivabradine to decrease the beating rate in hiPSC-EHTs were much greater than in spontaneously beating right atria/SAN preparations of adult wild-type mice examined under similar conditions (Mesirca et al., 2014; no effect at 50 nM, 50% reduction at 1,000 nM). The data mirror results of genetic deletion of HCN4 in mice, which was embryonically lethal (Stieber et al., 2003), indicating a greater role of  $I_f$  for pacemaking in the developing heart. On the other hand, the effect of isoprenaline, acting by stimulating both the cAMP-sensitive  $I_f$  and  $Ca^{2+}$  uptake into the SR, was smaller in hiPSC-EHTs than in native SAN preparations (+30% versus +50% in mice; Mesirca et al., 2014). The isoprenaline effect was blocked by ryanodine at a high concentration (10  $\mu$ M), suggesting that regulation of SR  $Ca^{2+}$  loading plays a major role in the isoprenaline-induced tachycardia in this model. Ryanodine itself reduced spontaneous beating frequency by 50%, similar to data in the intact canine SAN (Joung et al., 2009). Together with the rate-reducing effect of the NCX blocker SEA-0400 at



10  $\mu$ M, the data suggest that both calcium- and membrane-clock mechanisms contribute to pacemaking in hiPSC-EHTs and that membrane regulation by  $I_f$  is involved in these cells. The contribution of  $I_f$  is in line with previous electrophysiological characterization of hiPSC-CM (Ma et al., 2011), but has not been observed in another hiPSC-CM model (Zhang et al., 2015). Reasons for the difference are unknown, but the clear concentration and time dependence and low half maximal inhibitory concentration ( $IC_{50}$ ) of ivabradine in our experiments provide strong evidence for a specific effect. A suppression of spontaneous beating was also observed in the presence of TTX (1  $\mu$ M). While TTX-sensitive sodium currents are not assumed to play a role in pacemaking in the adult SAN, 50% of newborn rabbit SAN cells express TTX-sensitive sodium currents, and this fraction decreased to 10% in adult animals (Baruscotti et al., 1996). These data suggest that pacemaking mechanisms in hiPSC-CM/EHTs resemble that of newborn SAN cells.

Modulation of cardiac repolarization is a sensitive issue in drug development, and analyses of drug effects on one of the main repolarizing currents,  $I_{Kr}$ , assayed in human ether-a-go-go-related gene (hERG)-expressing cell lines, are mandatory (Kramer et al., 2013; Okada et al., 2015). EHTs are not well suited for the determination of action potentials (e.g., with sharp microelectrodes), but offer simple and robust measurements of contraction kinetics under steady-state conditions. We therefore tested the hypothesis that drug effects on cardiac repolarization of hiPSC-EHTs can be detected by affections of the relaxation time T2 as previously demonstrated in rat EHTs (Eder et al., 2014). Indeed, stimulators (i.e., inhibitors of inactivation) of the depolarizing fast sodium current  $I_{Na}$  (ATX-II), activators of L-type calcium current  $I_{Ca,L}$  (Bay K-8644), and inhibitors of the repolarizing rapidly activating delayed rectifier current  $I_{Kr}$  (E-4031) concentration-dependently prolonged T2, while activation of  $I_{Kr}$  with NS-1643 abbreviated T2. Threshold concentrations matched well with published  $IC_{50}$  or  $EC_{50}$  values on the respective channels (Figure 6). The Bay K-8644-mediated prolongation of relaxation time in spontaneously beating hiPSC-EHTs is in line with previous electrophysiological findings in hiPSC-CM, which revealed an atypical response to Bay K-8644 with a blunted increase in L-type calcium current amplitude and prolonged activation and inactivation kinetics (Kang et al., 2012; Ji et al., 2014). Effects of  $I_{Ks}$  current inhibition could not be demonstrated in hiPSC-EHT even under adrenergic stimulation and  $I_{Kr}$  block. This is in line with previous studies reporting small  $I_{Ks}$  currents of 0.31 pA/pF in 5 out of 16 analyzed hiPSC-CM (Ma et al., 2011) and insensitivity of hiPSC-CMs to  $I_{Ks}$  current inhibition in multi-electrode arrays under blinded conditions (Qu

and Vargas, 2015). The data collectively indicate that  $I_{Ks}$  contributes only little to repolarization of hiPSC-CM. Taken together, the experiments with model compounds show high sensitivity of hiPSC-EHTs in detecting the effects of ion-channel modulators as alteration in T2.  $I_{Ks}$  is a notable exception.

Obviously, T2 changes are not specific for certain alterations in ion current, as modulators with different modes of action (ATX-II, Bay K-8644, E-4031) all result in similar changes. Moreover, relaxation time was also prolonged by EMD-57033, a relatively pure calcium sensitizer that prolongs relaxation by its direct effect on the myofilaments, and relaxation time was shortened by the cAMP-dependent drugs isoprenaline and rolipram, acting via phosphorylation of PLN and several myofilament proteins (Figure 5). Interestingly, neither verapamil nor TTX affected relaxation time. Their effect was visible as a concentration-dependent decrease in force and rate, respectively. The lack of verapamil effects on T2 is important for two reasons. (1) It is consistent with the effect of varying extracellular  $Ca^{2+}$  concentrations, strongly affecting peak force but not contraction kinetics. (2) Verapamil blocks  $I_{Kr}$  in addition to  $I_{Ca,L}$  and is a classic example of a drug that would have failed in hERG assays, but has never been associated with proarrhythmic effects or QT prolongation. The lack of a T2 signal in hiPSC-EHTs is in line with clinical safety. Thus, the hiPSC-EHT system offers a high-content readout of contractile function, which integrates effects on depolarizing and repolarizing ion currents, myofilaments, and SR-based  $Ca^{2+}$  cycling without directly indicating the respective mechanism of action.

It seems, therefore, that this system is well suited for an initial screening of cardiac effects of drugs. The ability to detect the effects of ion-channel modulators was further challenged with a set of (previously) approved drugs, classified for their different potential to induce torsades-de-pointes arrhythmia (Redfern et al., 2003). The correlation depicted in Figure 7 demonstrates that prolongation of T2 in hiPSC-EHTs is a sensitive surrogate for APD<sub>90</sub> prolongation. Given the key role of APD prolongation in drug-induced cardiac proarrhythmia (Fermini et al., 2015), a surrogate for APD prolongation might address an important aspect of in vitro cardiac safety assessment. This conclusion is strengthened by the lack of T2 effects of four compounds known to be safe (aspirin, paracetamol, ampicillin, and verapamil).

In conclusion, this study analyzes the contractile force of hiPSC-CM in the hiPSC-EHT model. Characteristic changes in contractile force are described for several physiological and pharmacological assays replicating findings of ex vivo non-failing human heart tissue, suggesting a high versatility of the hiPSC-EHT model as in vitro test system.



## EXPERIMENTAL PROCEDURES

### Generation of Human Engineered Heart Tissue

Spontaneously beating cardiomyocytes (day 14 of differentiation culture; [Movies S4](#) and [S5](#)) were washed twice with PBS and digested with collagenase II (Worthington, LS004176; 200 U/ml Ca<sup>2+</sup>-free HBSS [Gibco, 14175-053] with 1 mM HEPES [pH 7.4], 10  $\mu$ M Y-27632, and 30  $\mu$ M N-benzyl-p-toluene sulfonamide [TCI, B3082]) for 3.5 hr at 37°C (5% CO<sub>2</sub>, 21% O<sub>2</sub>). The dissociated cells were washed (Ca<sup>2+</sup>-containing DMEM [Biochrom, F0415] with DNase [12  $\mu$ g/ml; Sigma-Aldrich, D8764]; centrifugation at 100  $\times$  g for 15 min) and resuspended in basic medium (Ca<sup>2+</sup>-containing DMEM with 1% penicillin/streptomycin). Cell count was determined (CASY) and cell concentration adjusted to 10–15  $\times$  10<sup>6</sup> cells/ml. For determination of differentiation efficiency, 2  $\times$  10<sup>5</sup> cells were subjected to fluorescence-activated cell sorting analysis with the directly labeled cTNT antibody (Miltenyi, 130-106-745; 1:10). Fibrin-based human EHTs were generated in agarose casting molds with solid silicone racks as previously described ([Hansen et al., 2010](#); [Schaaf et al., 2014](#)). In brief, casting molds were generated with agarose (2% in PBS [Invitrogen, 15510-019]) and custom-made Teflon spacers in 24-well plates (Nunc, 122475). Custom-made silicone racks were placed on the 24-well plates. Cells (final concentration 10  $\times$  10<sup>6</sup> cells/ml) were mixed with 100  $\mu$ l/ml Matrigel (BD Bioscience, 256235), 5 mg/ml bovine fibrinogen (200 mg/ml in NaCl 0.9% [Sigma, F4753] plus 0.5  $\mu$ g/mg aprotinin [Sigma, A1153]), and 2 $\times$  DMEM (matching the volume of fibrinogen and thrombin for isotonization), and EHTs were generated with 100  $\mu$ l per EHT (1  $\times$  10<sup>6</sup> cells), 10  $\mu$ M Y-27632, and 3 U/ml thrombin (100 U/ml [Biopur, BP11101104]). The cell mix was pipetted into agarose casting molds around silicone posts. After fibrin polymerization (37°C, 2 hr) the silicone racks with attached fibrin gels were transferred to new 24-well plates and cultured for 4–6 weeks (37°C, 40% O<sub>2</sub>, 7% CO<sub>2</sub>). The culture medium consisted of DMEM, 1% penicillin/streptomycin, 10% horse serum (Gibco, 26050), 10  $\mu$ g/ml insulin, and 33  $\mu$ g/ml aprotinin. Culture medium was changed on Mondays, Wednesdays, and Fridays. After 10–14 days in culture, human EHTs displayed spontaneous coherent, regular beating deflecting the silicone posts, and allowed video-optical contraction analysis. Commercial hiPSC-CM (CDI, iCell; Axiogenesis, Cor.4U) were used for comparison. Cells were thawed or dissociated according to instruction manuals, and cells counted (CASY) and EHTs prepared as stated above.

### Contractile Analysis of Human EHTs

Contractile analysis was performed on 20–40-day-old EHTs in modified Tyrode's solution (120 mM NaCl, 5.4 mM KCl, 1 mM MgCl<sub>2</sub>, 0.1–5 mM CaCl<sub>2</sub>, 0.4 mM NaH<sub>2</sub>PO<sub>4</sub>, 22.6 mM NaHCO<sub>3</sub>, 5 mM glucose, 0.05 mM Na<sub>2</sub>EDTA, and 25 mM HEPES) pre-equilibrated overnight (37°C, 7% CO<sub>2</sub>, 40% O<sub>2</sub>). Analysis of contractile force was performed by video-optical recording as previously described ([Hansen et al., 2010](#); [Schaaf et al., 2011](#); [Figure S1](#)) on a setup available from EHT Technologies. When indicated, EHTs were electrically stimulated (2 V, 0.5–5 Hz, impulse duration 4 ms) with carbon electrodes as previously described using a Grass S88X stimulator ([Hirt et al., 2014](#)).

The contraction peaks were analyzed in terms of frequency, force, and contraction (T1) and relaxation time (T2) at 80% of peak height ([Figure S3](#)).

### Statistical Analysis

According to journal guidelines, statistical analyses were only performed (GraphPad Prism software 5.0) for experiments with  $\geq 3$  independent experiments (EHTs from  $\geq 3$  independent cardiomyocyte differentiations). Data are expressed as mean  $\pm$  SEM in bar graphs (except [Figure S2](#): mean  $\pm$  SD) and curves, or as single values and mean in scatterplots. Data in the text are expressed as mean  $\pm$  SD. Differences between groups were analyzed by one-way ANOVA followed by Dunnett's (all compared with baseline) post hoc multiple comparisons. Results were considered statistically significant (\*) if the p value was less than 0.05. Average contraction peaks were generated from at least ten contraction peaks of several EHTs as indicated in the respective replicate number. These are depicted as mean  $\pm$  SEM.

## SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, seven figures, two tables, and five movies and can be found with this article online at <http://dx.doi.org/10.1016/j.stemcr.2016.04.011>.

## AUTHOR CONTRIBUTIONS

I.M., T.E., and A.H. conceived and organized the project and wrote the manuscript; I.M., K.B., D.L.-B., S.S., H.S., C.N., A.B., T.W., A.E., T.S., B.K., M.H., A.M., N.H., and T.C. contributed to experiments and data analysis. All authors discussed the results and commented on the manuscript.

## ACKNOWLEDGMENTS

We thank Lisa Krämer, Giulia Mearini, June Uebeler, Maksymilian Prondzynski, Sari Panjaitan, Bärbel Ulmer, Umber Saleem, Sandra Laufer, and Aya Shibamiya (HEXT Stem Cell Core Facility, UKE Hamburg) for their support. We greatly appreciate the assistance of Kristin Hartmann and Susanne Krasemann (HEXT Mouse Pathology Core Facility, UKE Hamburg), in processing histological and TEM samples. This study was supported by Deutsche Forschungsgemeinschaft (DFG Es 88/12-1, DFG Ha 3/1), the British National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs CRACK-IT grant 35911-259146), the European Research Council (ERC-AG IndivUHeart), the EU (FP7 Biodesign), the German Centre for Cardiovascular Research (DZHK), and the German Ministry of Education and Research (BMBF), British Heart Foundation RM/13/30157, the German Heart Foundation, the Freie und Hansestadt Hamburg, and Era-Net E-RARE (01GM1305). I.M., A.E., M.H., T.E., and A.H. are co-founders of EHT Technologies GmbH, Hamburg.

Received: December 9, 2015

Revised: April 20, 2016

Accepted: April 22, 2016

Published: May 19, 2016



## REFERENCES

- Baruscotti, M., DiFrancesco, D., and Robinson, R.B. (1996). A TTX-sensitive inward sodium current contributes to spontaneous activity in newborn rabbit sino-atrial node cells. *J. Physiol.* *492*, 21–30.
- Bechem, M., and Schramm, M. (1987). Calcium-agonists. *J. Mol. Cell. Cardiol.* *19 (Suppl 2)*, 63–75.
- Boucek, R.J., Citak, M., Graham, T.P., and Artman, M. (1987). Effects of postnatal maturation on postrest potentiation in isolated rabbit atria. *Pediatr. Res.* *22*, 524–530.
- Braam, S.R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., and Mummery, C.L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. *Stem Cell Res.* *4*, 107–116.
- Burridge, P.W., Keller, G., Gold, J.D., and Wu, J.C. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. *Cell Stem Cell* *10*, 16–28.
- Casis, O., Olesen, S.-P., and Sanguinetti, M.C. (2006). Mechanism of action of a novel human ether-a-go-go-related gene channel activator. *Mol. Pharmacol.* *69*, 658–665.
- Caspi, O., Itzhaki, I., Kehat, I., Gepstein, A., Arbel, G., Huber, I., Satin, J., and Gepstein, L. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. *Stem Cells Dev.* *18*, 161–172.
- Clements, M., and Thomas, N. (2014). High-throughput multiparameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. *Toxicol. Sci.* *140*, 445–461.
- Eder, A., Hansen, A., Uebeler, J., Schulze, T., Neuber, C., Schaaf, S., Yuan, L., Christ, T., Vos, M.A., and Eschenhagen, T. (2014). Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. *Basic Res. Cardiol.* *109*, 436.
- Eschenhagen, T., Eder, A., Vollert, I., and Hansen, A. (2012). Physiological aspects of cardiac tissue engineering. *Am. J. Physiol. Heart Circ. Physiol.* *303*, H133–H143.
- Feaster, T.K., Cadar, A.G., Wang, L., Williams, C.H., Chun, Y.W., Hempel, J.E., Bloodworth, N., Merryman, W.D., Lim, C.C., Wu, J.C., et al. (2015). Matrigel mattress: a method for the generation of single contracting human-induced pluripotent stem cell-derived cardiomyocytes. *Circ. Res.* *117*, 995–1000.
- Fermini, B., Hancox, J.C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K.W., Colatsky, T., Correll, K., Crumb, W., Damiano, B., Erdemli, G., et al. (2015). A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. *J. Biomol. Screen.* *21*, 1–11.
- Ferrantini, C., Coppini, R., Sacconi, L., Tosi, B., Zhang, M.L., Wang, G.L., de Vries, E., Hoppenbrouwers, E., Pavone, F., Cerbai, E., et al. (2014). Impact of detubulation on force and kinetics of cardiac muscle contraction. *J. Gen. Physiol.* *143*, 783–797.
- Ferry, D.R., Glossmann, H., and Kaumann, A.J. (1985). Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. *Br. J. Pharmacol.* *84*, 811–824.
- Francis, G.S., Bartos, J.A., and Adaty, S. (2014). Inotropes. *J. Am. Coll. Cardiol.* *63*, 2069–2078.
- Gómez, A.M., Valdivia, H.H., Cheng, H., Lederer, M.R., Santana, L.F., Cannell, M.B., McCune, S.A., Altschuld, R.A., and Lederer, W.J. (1997). Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. *Science* *276*, 800–806.
- Guo, L., Coyle, L., Abrams, R.M.C., Kemper, R., Chiao, E.T., and Kolaja, K.L. (2013). Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. *Toxicol. Sci.* *136*, 581–594.
- Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwoerer, A.P., Uebeler, J., and Eschenhagen, T. (2010). Development of a drug screening platform based on engineered heart tissue. *Circ. Res.* *107*, 35–44.
- Harris, K., Aylott, M., Cui, Y., Louttit, J.B., McMahon, N.C., and Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. *Toxicol. Sci.* *134*, 412–426.
- Hirt, M.N., Sörensen, N.A., Bartholdt, L.M., Boeddinghaus, J., Schaaf, S., Eder, A., Vollert, I., Stöhr, A., Schulze, T., Witten, A., et al. (2012). Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. *Basic Res. Cardiol.* *107*, 307.
- Hirt, M.N., Hansen, A., and Eschenhagen, T. (2014). Cardiac tissue engineering: state of the art. *Circ. Res.* *114*, 354–367.
- Hoekstra, M., Mummery, C.L., Wilde, A.A., Bezzina, C.R., and Verkerk, A.O. (2012). Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. *Front. Physiol.* *3*, 346.
- Ji, J., Kang, J., and Rampe, D. (2014). L-type Ca(2+) channel responses to Bay K 8644 in stem cell-derived cardiomyocytes are unusually dependent on holding potential and charge carrier. *Assay Drug Dev. Technol.* *12*, 352–360.
- Jost, N., Virág, L., Bitay, M., Takács, J., Lengyel, C., Biliczki, P., Nagy, Z., Bogáts, G., Lathrop, D.A., Papp, J.G., et al. (2005). Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. *Circulation* *112*, 1392–1399.
- Joung, B., Tang, L., Maruyama, M., Han, S., Chen, Z., Stucky, M., Jones, L.R., Fishbein, M.C., Weiss, J.N., Chen, P.-S., et al. (2009). Intracellular calcium dynamics and acceleration of sinus rhythm by beta-adrenergic stimulation. *Circulation* *119*, 788–796.
- Kang, J., Chen, X., Ji, J., Lei, Q., and Rampe, D. (2012). Ca<sup>2+</sup> channel activators reveal differential L-type Ca<sup>2+</sup> channel pharmacology between native and stem cell-derived cardiomyocytes. *J. Pharmacol. Exp. Ther.* *341*, 510–517.
- Karakikes, I., Ameen, M., Termglinchan, V., and Wu, J.C. (2015). Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. *Circ. Res.* *117*, 80–88.
- Kaufmann, S.G., Westenbroek, R.E., Maass, A.H., Lange, V., Renner, A., Wischmeyer, E., Bonz, A., Muck, J., Ertl, G., Catterall, W.A., et al. (2013). Distribution and function of sodium channel subtypes in human atrial myocardium. *J. Mol. Cell. Cardiol.* *61*, 133–141.
- Kensah, G., Roa Lara, A., Dahlmann, J., Zweigerdt, R., Schwanke, K., Hegemann, J., Skvorc, D., Gawol, A., Azizian, A., Wagner, S., et al. (2013). Murine and human pluripotent stem cell-derived



- cardiac bodies form contractile myocardial tissue in vitro. *Eur. Heart J.* *34*, 1134–1146.
- Kramer, J., Obejero-Paz, C.A., Myatt, G., Kuryshev, Y.A., Bruening-Wright, A., Verducci, J.S., and Brown, A.M. (2013). MICE models: superior to the HERG model in predicting Torsade de Pointes. *Sci. Rep.* *3*, 2100.
- Kuppusamy, K.T., Jones, D.C., Sperber, H., Madan, A., Fischer, K.A., Rodriguez, M.L., Pabon, L., Zhu, W.-Z., Tulloch, N.L., Yang, X., et al. (2015). Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. *Proc. Natl. Acad. Sci. USA* *112*, E2785–E2794.
- Lakatta, E.G., Maltsev, V.A., and Vinogradova, T.M. (2010). A coupled SYSTEM of intracellular Ca<sup>2+</sup> clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. *Circ. Res.* *106*, 659–673.
- Lee, P., Klos, M., Bollensdorff, C., Hou, L., Ewart, P., Kamp, T.J., Zhang, J., Bizy, A., Guerrero-Serna, G., Kohl, P., et al. (2012). Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. *Circ. Res.* *110*, 1556–1563.
- Lopez-Izquierdo, A., Warren, M., Riedel, M., Cho, S., Lai, S., Lux, R.L., Spitzer, K.W., Benjamin, I.J., Tristani-Firouzi, M., and Jou, C.J. (2014). A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes. *Am. J. Physiol. Heart Circ. Physiol.* *307*, H1370–H1377.
- Lundy, S.D., Zhu, W.-Z., Regnier, M., and Laflamme, M.A. (2013). Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. *Stem Cells Dev.* *22*, 1991–2002.
- Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja, K.L., Swanson, B.J., and January, C.T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. *Am. J. Physiol. Heart Circ. Physiol.* *301*, H2006–H2017.
- Mesirca, P., Alig, J., Torrente, A.G., Müller, J.C., Marger, L., Rollin, A., Marquilly, C., Vincent, A., Dubel, S., Bidaud, I., et al. (2014). Cardiac arrhythmia induced by genetic silencing of “funny” (f) channels is rescued by GIRK4 inactivation. *Nat. Commun.* *5*, 4664.
- Moretti, A., Laugwitz, K.-L., Dorn, T., Sinnecker, D., and Mummery, C. (2013). Pluripotent stem cell models of human heart disease. *Cold Spring Harb. Perspect. Med.* *3*, a014027.
- Naito, H., Melnychenko, I., Didié, M., Schneiderbanger, K., Schubert, P., Rosenkranz, S., Eschenhagen, T., and Zimmermann, W.-H. (2006). Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. *Circulation* *114*, 172–178.
- Navarrete, E.G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P.W., Patlolla, B., Lee, A.S., et al. (2013). Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. *Circulation* *128*, S3–S13.
- Nishimura, S., Yasuda, S., Kato, M., Yamada, K.P., Yamashita, H., Saeki, Y., Sunagawa, K., Nagai, R., Hisada, T., and Sugiura, S. (2004). Single cell mechanics of rat cardiomyocytes under isometric, unloaded, and physiologically loaded conditions. *Am. J. Physiol. Heart Circ. Physiol.* *287*, H196–H202.
- Nunes, S.S., Miklas, J.W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013). Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. *Nat. Methods* *10*, 781–787.
- Okada, J.-I., Yoshinaga, T., Kurokawa, J., Washio, T., Furukawa, T., Sawada, K., Sugiura, S., and Hisada, T. (2015). Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator. *Sci. Adv.* *1*, e1400142.
- Oliveira, J.S., Redaelli, E., Zaharenko, A.J., Cassulini, R.R., Konno, K., Pimenta, D.C., Freitas, J.C., Clare, J.J., and Wanke, E. (2004). Binding specificity of sea anemone toxins to Nav 1.1–1.6 sodium channels. Unexpected contributions from differences in the IV/S3–S4 outer loop. *J. Biol. Chem.* *279*, 33323–33335.
- Pointon, A., Harmer, A.R., Dale, I.L., Abi-Gerges, N., Bowes, J., Pollard, C., and Garside, H. (2015). Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. *Toxicol. Sci.* *144*, 227–237.
- Qu, Y., and Vargas, H.M. (2015). Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the maestro MEA platform. *Toxicol. Sci.* *147*, 286–295.
- Redfern, W., Carlsson, L., Davis, A., Lynch, W., Mackenzie, I., Palethorpe, S., Siegl, P., Strang, I., Sullivan, A., and Wallis, R. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. *Cardiovasc. Res.* *58*, 32–45.
- Riedel, M., Jou, C.J., Lai, S., Lux, R.L., Moreno, A.P., Spitzer, K.W., Christians, E., Tristani-Firouzi, M., and Benjamin, I.J. (2014). Functional and pharmacological analysis of cardiomyocytes differentiated from human peripheral blood mononuclear-derived pluripotent stem cells. *Stem Cell Rep.* *3*, 131–141.
- Schaaf, S., Shibamiya, A., Mewe, M., Eder, A., Stöhr, A., Hirt, M.N., Rau, T., Zimmermann, W.-H., Conradi, L., Eschenhagen, T., et al. (2011). Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. *PLoS One* *6*, e26397.
- Schaaf, S., Eder, A., Vollert, I., Stöhr, A., Hansen, A., and Eschenhagen, T. (2014). Generation of strip-format fibrin-based engineered heart tissue (EHT). *Methods Mol. Biol.* *1181*, 121–129.
- Scott, C.W., Zhang, X., Abi-Gerges, N., Lamore, S.D., Abassi, Y.A., and Peters, M.F. (2014). An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. *Toxicol. Sci.* *142*, 331–338.
- Stieber, J., Herrmann, S., Feil, S., Löster, J., Feil, R., Biel, M., Hofmann, F., and Ludwig, A. (2003). The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart. *Proc. Natl. Acad. Sci. USA* *100*, 15235–15240.
- Sutko, J.L., and Willerson, J.T. (1980). Ryanodine alteration of the contractile state of rat ventricular myocardium. Comparison with dog, cat, and rabbit ventricular tissues. *Circ. Res.* *46*, 332–343.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent



- stem cells from adult human fibroblasts by defined factors. *Cell* *131*, 861–872.
- Thavandiran, N., Dubois, N., Mikryukov, A., Massé, S., Beca, B., Simmons, C.A., Deshpande, V.S., McGarry, J.P., Chen, C.S., Nanthakumar, K., et al. (2013). Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. *Proc. Natl. Acad. Sci. USA* *110*, E4698–E4707.
- Tulloch, N.L., Muskheli, V., Razumova, M.V., Korte, F.S., Regnier, M., Hauch, K.D., Pabon, L., Reinecke, H., and Murry, C.E. (2011). Growth of engineered human myocardium with mechanical loading and vascular coculture. *Circ. Res.* *109*, 47–59.
- Wiegerinck, R.F., Cojoc, A., Zeidenweber, C.M., Ding, G., Shen, M., Joyner, R.W., Fernandez, J.D., Kanter, K.R., Kirshbom, P.M., Kogon, B.E., et al. (2009). Force frequency relationship of the human ventricle increases during early postnatal development. *Pediatr. Res.* *65*, 414–419.
- Yang, X., Pabon, L., and Murry, C.E. (2014). Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. *Circ. Res.* *114*, 511–523.
- Zhang, X.-H., Wei, H., Šarić, T., Hescheler, J., Cleemann, L., and Morad, M. (2015). Regionally diverse mitochondrial calcium signaling regulates spontaneous pacing in developing cardiomyocytes. *Cell Calcium* *57*, 321–336.
- Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J.C., Robertson, G.A., and January, C.T. (1998). Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. *Biophys. J.* *74*, 230–241.